Kaya Vildan, Yıldırım Mustafa, Yazıcı Gözde, Yalçın Ayşen Yeşim, Orhan Nuri, Güzel Aslan
Medstar Antalya Hospital, Department of Radiation Oncology, Antalya, Turkey. Email:
Asian Pac J Cancer Prev. 2017 Dec 29;18(12):3287-3291. doi: 10.22034/APJCP.2017.18.12.3287.
Background: High-grade gliomas, with glioblastomas as the most frequently observed histologic subtype, are the most common primary brain tumours in adults. It is considered that inflammatory responses play a major role in malignancies, including tumour progression. This study aimed to determine the prognostic significance of the neutrophil to lymphocyte ratio (NLR) and the thrombocyte to lymphocyte ratio (PLR) as indicators of systemic inflammatory response (SIR) in glioblastoma patients. Methods: A total of 90 patients treated for glioblastoma were retrospectively evaluated. Absolute counts were used to generate NLR and PLR. A SIR was considered to be present with an NLR ≥5 and/or PLR ≥150. Results: Median follow-up time was 11.3 months (range: 1-70 months). The 1-year and 2-year overall survival rates were 55.2% and 19.5%, respectively. Univariate analysis showed that there was no correlation between overall survival and gender (p=0.184), comorbid disease (p = 0.30), clinical presentation (p = 0.884), or tumour lateralization (p = 0.159). Multivariate analysis showed that overall survival was significantly correlated with SIR based on NLR (HR: 2.41), and ECOG performance status (HR: 1.53). The prognostic factors that affected survival, other than SIR, were Eastern Cooperative Oncology Group (ECOG) performance status (p = 0.003), and tumour localization (p = 0.006). Conclusion: The present findings confirm that NLR based on peripheral blood counts prior to treatment can be used as a prognostic factor in patients with glioblastoma. Since tumour aggression increases and survival decreases as the NLR value rises, choice of treatment modality is facilitated for glioblastoma patients.
高级别胶质瘤是成人中最常见的原发性脑肿瘤,其中胶质母细胞瘤是最常见的组织学亚型。炎症反应被认为在包括肿瘤进展在内的恶性肿瘤中起主要作用。本研究旨在确定中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR)作为胶质母细胞瘤患者全身炎症反应(SIR)指标的预后意义。方法:回顾性评估了90例接受胶质母细胞瘤治疗的患者。采用绝对计数法计算NLR和PLR。当NLR≥5和/或PLR≥150时,认为存在SIR。结果:中位随访时间为11.3个月(范围:1 - 70个月)。1年和2年总生存率分别为55.2%和19.5%。单因素分析显示,总生存与性别(p = 0.184)、合并疾病(p = 0.30)、临床表现(p = 0.884)或肿瘤定位(p = 0.159)之间无相关性。多因素分析显示,基于NLR的SIR(HR:2.41)和东部肿瘤协作组(ECOG)体能状态(HR:1.53)与总生存显著相关。除SIR外,影响生存的预后因素为ECOG体能状态(p = 0.003)和肿瘤定位(p = 0.006)。结论:本研究结果证实,治疗前基于外周血细胞计数的NLR可作为胶质母细胞瘤患者的预后因素。由于随着NLR值升高肿瘤侵袭性增加且生存降低,这有助于胶质母细胞瘤患者选择治疗方式。